Lonza launched TWK10, a probiotic strain isolated from naturally fermented Taiwanese kimchi designed for athletes and active consumers.
Photo © iStockphoto.com
Lonza (Morristown, NJ) launched TWK10, a Lactobacillus plantarum probiotic strain isolated from naturally fermented Taiwanese kimchi designed for athletes and active consumers. The clean-label, vegan-friendly ingredient has been clinically shown to enhance endurance, improve body composition and energy levels, and modulate gut microbiota. It is licensed exclusively from Synbiotech for North America and Europe
“At Lonza, we continue to look for and develop science-backed ingredients to help brands create cleaner, more effective products that active consumers demand,” said Thomas Kiy, PhD, vice president strategy and portfolio development at Lonza Capsules & Health Ingredients, in a press release. “TWK10 probiotic is a world-first for the sports nutrition market, and a true innovation.”
Kuei-Ming Lee, vice president of Human Healthcare of Synbiotech, said: “Fermented dairy products with active bacterial cultures are the typical source of many probiotics currently on the market. However, our extensive research exploring over 300 plant-derived probiotic strains revealed a unique strain with excellent survival rates. Currently two human clinical trials have been completed on TWK10 probiotic, and studies have shown that it delivers significant benefits for fitness enthusiasts and active individuals, including increasing muscle endurance.”
TWK10 will be officially unveiled at Lonza’s Virtual Innovation Day on Oct. 1, 2020.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.